132 related articles for article (PubMed ID: 22345163)
1. Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity.
Moisan F; Laroche-Clary A; Auzanneau C; Ricard N; Pourquier P; Robert J; Le Morvan V
Carcinogenesis; 2012 May; 33(5):962-8. PubMed ID: 22345163
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of two human transcription factor IIH (TFIIH)-related complexes: ERCC2/CAK and TFIIH.
Reardon JT; Ge H; Gibbs E; Sancar A; Hurwitz J; Pan ZQ
Proc Natl Acad Sci U S A; 1996 Jun; 93(13):6482-7. PubMed ID: 8692841
[TBL] [Abstract][Full Text] [Related]
3. Lack of CAK complex accumulation at DNA damage sites in XP-B and XP-B/CS fibroblasts reveals differential regulation of CAK anchoring to core TFIIH by XPB and XPD helicases during nucleotide excision repair.
Zhu Q; Wani G; Sharma N; Wani A
DNA Repair (Amst); 2012 Dec; 11(12):942-50. PubMed ID: 23083890
[TBL] [Abstract][Full Text] [Related]
4. XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase.
Fuss JO; Tainer JA
DNA Repair (Amst); 2011 Jul; 10(7):697-713. PubMed ID: 21571596
[TBL] [Abstract][Full Text] [Related]
5. GTF2E2 Mutations Destabilize the General Transcription Factor Complex TFIIE in Individuals with DNA Repair-Proficient Trichothiodystrophy.
Kuschal C; Botta E; Orioli D; Digiovanna JJ; Seneca S; Keymolen K; Tamura D; Heller E; Khan SG; Caligiuri G; Lanzafame M; Nardo T; Ricotti R; Peverali FA; Stephens R; Zhao Y; Lehmann AR; Baranello L; Levens D; Kraemer KH; Stefanini M
Am J Hum Genet; 2016 Apr; 98(4):627-42. PubMed ID: 26996949
[TBL] [Abstract][Full Text] [Related]
6. Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel.
Le Morvan V; Bellott R; Moisan F; Mathoulin-Pélissier S; Bonnet J; Robert J
Pharmacogenomics; 2006 Sep; 7(6):843-52. PubMed ID: 16981845
[TBL] [Abstract][Full Text] [Related]
7. Role of XPD in cellular functions: To TFIIH and beyond.
Houten BV; Kuper J; Kisker C
DNA Repair (Amst); 2016 Aug; 44():136-142. PubMed ID: 27262611
[TBL] [Abstract][Full Text] [Related]
8. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human glioma.
Chen H; Shao C; Shi H; Mu Y; Sai K; Chen Z
J Neurooncol; 2007 May; 82(3):257-62. PubMed ID: 17151930
[TBL] [Abstract][Full Text] [Related]
9. Xpd/Ercc2 regulates CAK activity and mitotic progression.
Chen J; Larochelle S; Li X; Suter B
Nature; 2003 Jul; 424(6945):228-32. PubMed ID: 12853965
[TBL] [Abstract][Full Text] [Related]
10. TFIIH subunit alterations causing xeroderma pigmentosum and trichothiodystrophy specifically disturb several steps during transcription.
Singh A; Compe E; Le May N; Egly JM
Am J Hum Genet; 2015 Feb; 96(2):194-207. PubMed ID: 25620205
[TBL] [Abstract][Full Text] [Related]
11. Arsenic-induced promoter hypomethylation and over-expression of ERCC2 reduces DNA repair capacity in humans by non-disjunction of the ERCC2-Cdk7 complex.
Paul S; Banerjee N; Chatterjee A; Sau TJ; Das JK; Mishra PK; Chakrabarti P; Bandyopadhyay A; Giri AK
Metallomics; 2014 Apr; 6(4):864-73. PubMed ID: 24473091
[TBL] [Abstract][Full Text] [Related]
12. ERCC2/XPD Lys751Gln alter DNA repair efficiency of platinum-induced DNA damage through P53 pathway.
Zhang G; Guan Y; Zhao Y; van der Straaten T; Xiao S; Xue P; Zhu G; Liu Q; Cai Y; Jin C; Yang J; Wu S; Lu X
Chem Biol Interact; 2017 Feb; 263():55-65. PubMed ID: 28027876
[TBL] [Abstract][Full Text] [Related]
13. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines.
Weaver DA; Crawford EL; Warner KA; Elkhairi F; Khuder SA; Willey JC
Mol Cancer; 2005 May; 4(1):18. PubMed ID: 15882455
[TBL] [Abstract][Full Text] [Related]
14. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Van Allen EM; Mouw KW; Kim P; Iyer G; Wagle N; Al-Ahmadie H; Zhu C; Ostrovnaya I; Kryukov GV; O'Connor KW; Sfakianos J; Garcia-Grossman I; Kim J; Guancial EA; Bambury R; Bahl S; Gupta N; Farlow D; Qu A; Signoretti S; Barletta JA; Reuter V; Boehm J; Lawrence M; Getz G; Kantoff P; Bochner BH; Choueiri TK; Bajorin DF; Solit DB; Gabriel S; D'Andrea A; Garraway LA; Rosenberg JE
Cancer Discov; 2014 Oct; 4(10):1140-53. PubMed ID: 25096233
[TBL] [Abstract][Full Text] [Related]
15. The ERCC2/XPD Lys751Gln polymorphism affects DNA repair of benzo[a]pyrene induced damage, tested in an in vitro model.
Xiao S; Cui S; Lu X; Guan Y; Li D; Liu Q; Cai Y; Jin C; Yang J; Wu S; van der Straaten T
Toxicol In Vitro; 2016 Aug; 34():300-308. PubMed ID: 27139774
[TBL] [Abstract][Full Text] [Related]
16. The human DNA repair gene, ERCC2 (XPD), corrects ultraviolet hypersensitivity and ultraviolet hypermutability of a shuttle vector replicated in xeroderma pigmentosum group D cells.
Gözükara EM; Parris CN; Weber CA; Salazar EP; Seidman MM; Watkins JF; Prakash L; Kraemer KH
Cancer Res; 1994 Jul; 54(14):3837-44. PubMed ID: 8033104
[TBL] [Abstract][Full Text] [Related]
17. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
18. Abnormal XPD-induced nuclear receptor transactivation in DNA repair disorders: trichothiodystrophy and xeroderma pigmentosum.
Zhou X; Khan SG; Tamura D; Ueda T; Boyle J; Compe E; Egly JM; DiGiovanna JJ; Kraemer KH
Eur J Hum Genet; 2013 Aug; 21(8):831-7. PubMed ID: 23232694
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of nucleotide excision repair defects between XPD-mutated fibroblasts derived from trichothiodystrophy and xeroderma pigmentosum patients.
Nishiwaki T; Kobayashi N; Iwamoto T; Yamamoto A; Sugiura S; Liu YC; Sarasin A; Okahashi Y; Hirano M; Ueno S; Mori T
DNA Repair (Amst); 2008 Dec; 7(12):1990-8. PubMed ID: 18817897
[TBL] [Abstract][Full Text] [Related]
20. XPG stabilizes TFIIH, allowing transactivation of nuclear receptors: implications for Cockayne syndrome in XP-G/CS patients.
Ito S; Kuraoka I; Chymkowitch P; Compe E; Takedachi A; Ishigami C; Coin F; Egly JM; Tanaka K
Mol Cell; 2007 Apr; 26(2):231-43. PubMed ID: 17466625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
